Blood Plasma Market Outlook: Growth, Share, Value, Size, and Insights

Posted on 2024-10-21 16:35:50

"Blood Plasma Market Size And Forecast by 2031

Data Bridge Market Research analyses that the Global Blood Plasma Market which was USD 25.84 Billion in 2021 is expected to reach USD 63.33 Million by 2029 and is expected to undergo a CAGR of 10.60% during the forecast period of 2021 to 2029

Blood Plasma Market research report provides a comprehensive analysis of the market. The report aims to provide insights into Blood Plasma Market trends, growth opportunities, key drivers and challenges, competitive landscape, and other crucial factors that may impact the market in the forecast period (2024-2031).

Get a Sample PDF of Report - https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-blood-plasma-market

Which are the top companies operating in the Blood Plasma Market?

The study report on the Global Blood Plasma Market offers a comprehensive analysis of the industry, highlighting key trends, market dynamics, and competitive landscape. It profiles prominent organizations operating in the market, examining their successful strategies and market share contributions. This Blood Plasma Market report provides the information of the Top 10 Companies in Blood Plasma Market in the market their business strategy, financial situation etc.

**Segments**

- **Product Type**: The blood plasma market can be segmented based on product type into immunoglobulins, albumin, hyperimmune globulin, coagulation factor concentrates, and others. Immunoglobulins are expected to dominate the market due to their wide range of therapeutic applications and increasing demand for intravenous immunoglobulin (IVIg) in the treatment of various autoimmune diseases.

- **Application**: Based on application, the market can be divided into autoimmune diseases, hemophilia, primary immunodeficiency disorder, infectious diseases, and other applications. The autoimmune diseases segment is anticipated to witness significant growth owing to the rising prevalence of autoimmune disorders globally.

- **End-User**: The blood plasma market is categorized by end-user into hospitals, clinics, research laboratories, and others. Hospitals are the primary end-users of blood plasma products due to the high patient footfall seeking treatment for various medical conditions that require blood plasma therapies.

**Market Players**

- **CSL Limited**: CSL Limited is a key player in the global blood plasma market, offering a wide range of plasma-derived therapies for treating immunodeficiency disorders, hemophilia, and autoimmune diseases.

- **Grifols, S.A.**: Grifols is a leading player in the market known for its plasma-derived products like immunoglobulins, albumin, and coagulation factors, catering to the needs of patients with rare diseases.

- **Octapharma AG**: Octapharma specializes in producing human protein products from plasma, such as immunoglobulins and coagulation factors, contributing to the growth of the blood plasma market.

- **Shire (Takeda Pharmaceutical Company Limited)**: Shire, a subsidiary of Takeda, is involved in the development and distribution of plasma-derived products for treating hemophilia, immunodeficiency disorders, and other rare conditions.

The global blood plasma market is witnessing substantial growth driven by factors such as an increasing prevalence of autoimmune diseasesThe global blood plasma market continues to experience significant growth, propelled by various factors such as the rising prevalence of autoimmune diseases, hemophilia, and primary immunodeficiency disorders. The market segmentation based on product type highlights the dominance of immunoglobulins, attributed to their extensive therapeutic applications and the growing demand for intravenous immunoglobulin in the treatment of autoimmune diseases. This trend is further supported by the increasing incidence of autoimmune disorders globally, driving the growth of the autoimmune diseases segment within the market. With hospitals being the primary end-users of blood plasma products, the segment is expected to witness sustained demand due to the continuous influx of patients seeking treatment that requires blood plasma therapies.

Leading market players such as CSL Limited, Grifols, S.A., Octapharma AG, and Shire (Takeda Pharmaceutical Company Limited) play pivotal roles in shaping the competitive landscape of the blood plasma market. CSL Limited's diverse portfolio of plasma-derived therapies for immunodeficiency disorders, hemophilia, and autoimmune diseases solidifies its position as a key player in the industry. Grifols is renowned for its range of plasma-derived products, including immunoglobulins, albumin, and coagulation factors, catering to the specific needs of patients with rare diseases. Similarly, Octapharma's focus on producing human protein products from plasma, such as immunoglobulins and coagulation factors, contributes significantly to the market's growth trajectory. Shire, as a subsidiary of Takeda, actively participates in the development and distribution of plasma-derived products for treating hemophilia, immunodeficiency disorders, and other rare conditions, further diversifying the market offerings and meeting the healthcare needs of patients worldwide.

Moreover, the blood plasma market's expansion is driven by technological advancements in plasma fractionation processes, ensuring the efficient production of high-quality plasma-derived products to meet the increasing demand. Additionally, strategic collaborations, partnerships, and investments in research and development activities by key market players contribute to the market's competitiveness and innovation**Market Players**

- Allergan (Ireland)
- AbbVie Inc. (US)
- GALDERMA (Switzerland)
- Evolus, Inc. (US)
- Revance (US)
- HUGEL, Inc. (South Korea)
- Ipsen Pharma (France)
- USWM, LLC. (US)
- Sun Pharmaceutical Industries Ltd. (India)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Merz Pharma (Germany)
- Medytox (South Korea)
- Smith+Nephew (US)
- Sanofi (France)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- LGM Pharma. (US)
- Lannett (US)
- NorthStar Rx LLC (US)
- Par Pharmaceutical (US)

The global blood plasma market is experiencing significant expansion, driven by several key factors. The prevalence of autoimmune diseases, hemophilia, and primary immunodeficiency disorders is on the rise, fueling the demand for blood plasma products. Immunoglobulins stand out as a dominant product type in the market, primarily due to their versatile therapeutic applications and the increasing usage of intravenous immunoglobulin in treating autoimmune diseases. This trend is complemented by the growing incidence of autoimmune disorders worldwide, which is expected to boost the autoimmune diseases segment within the market. Given that hospitals serve as the primary end-users of blood plasma products,

Explore Further Details about This Research Blood Plasma Market Report https://www.databridgemarketresearch.com/reports/global-blood-plasma-market

Regional Analysis For Blood Plasma Market

North America (the United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, and Italy)

Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

South America (Brazil, Argentina, Colombia, etc.)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Why B2B Companies Worldwide Rely on us to Grow and Sustain Revenues:

Get a clear understanding of the Blood Plasma Market, how it operates, and the various stages of the value chain.
Understand the current market situation and future growth potential of the Blood Plasma Market throughout the forecast period.
Strategize marketing, market-entry, market expansion, and other business plans by understanding factors influencing growth in the market and purchase decisions of buyers.
Understand your competitors’ business structures, strategies, and prospects, and respond accordingly.
Make more informed business decisions with the help of insightful primary and secondary research sources.

This report provides Global Blood Plasma Market :

An in-depth overview of the global market for
Blood Plasma Market Assessment of the global industry trends, historical data from 2015, projections for the coming years, and anticipation of compound annual growth rates (CAGRs) by the end of the forecast period.
Discoveries of new market prospects and targeted marketing methodologies for Global Blood Plasma Market
Discussion of R&D, and the demand for new products launches and applications.
Wide-ranging company profiles of leading participants in the industry.
The composition of the market, in terms of dynamic molecule types and targets, underlining the major industry resources and players.
The growth in patient epidemiology and market revenue for the market globally and across the key players and Blood Plasma Market segments.
Study the market in terms of generic and premium product revenue.
Determine commercial opportunities in the market sales scenario by analyzing trends in authorizing and co-development deals.

Understanding market trends and industry insights at a regional level is essential for effective decision-making. Our reports are available in multiple regional languages to cater to diverse audiences. These localized reports provide in-depth analyses tailored to specific regions, ensuring businesses and stakeholders can access accurate and relevant information. By offering insights in local languages, we aim to bridge communication gaps and empower regional markets with the knowledge they need to grow and thrive. Explore our reports in your preferred language for a more personalized understanding of industry dynamics.

Data Bridge Market Research:

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC: +653 1251 1131

Email:- [email protected]"